Opthea Ltd (ASX: OPT) Share Price and News
Price
$0.60
Movement
0.00 (0.0)
as at 19 Jun - Closed (20 mins delayed)
52 Week Range
$0.335 - $1.165
1 Year Return
+62.16%
Opthea Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$738.77 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.23 billion
Earnings per share
-0.282
Dividend per share
N/A
Year To Date Return
-25.93%
Earnings Yield
N/A
Franking
-
Share Price
$0.60
Day Change
0.00 (0.0)
52 Week Range
$0.335 - $1.165
Yesterday's Close
$0.60
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
0
Turnover
$0
as at 19 Jun - Closed
Opthea Ltd (ASX: OPT)
Latest News
Share Fallers
Why Afterpay, Atomo, Opthea, & Sealink shares are falling today
Small Cap Shares
4 small cap ASX shares to watch
Share Fallers
Why Nanosonics, Oil Search, Opthea, & Piedmont Lithium are tumbling
Share Market News
Why Bigtincan, Oil Search, Opthea, & Xref shares are racing higher
Healthcare Shares
Here's why the Opthea (ASX:OPT) share price is soaring 8%
Share Gainers
Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher
Share Gainers
Why the Opthea (ASX:OPT) share price is rocketing 12% higher
Healthcare Shares
The ASX healthcare shares Goldman Sachs rates as a buy
Share Gainers
Why Aristocrat Leisure, Opthea, PointsBet, & Spirit are storming higher:
Share Market News
The Opthea (ASX:OPT) share price up after receiving FDA approval
Share Gainers
Why Codan, Evolution, Opthea, & People Infrastructure shares are charging higher
Share Market News
Why the Opthea (ASX:OPT) share price is soaring 11% today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 2nd Jun 2025 2025-06-02T09:14:26 | Final Director's Interest Notice Quinton Oswald | YesNo | 9:14am | 2 | 883k |
| 2nd Jun 2025 2025-06-02T09:13:36 | Final Director's Interest Notice Dr Susan Orr | YesNo | 9:13am | 2 | 883k |
| 2nd Jun 2025 2025-06-02T09:13:26 | Final Director's Interest Notice Dr Julia Haller | YesNo | 9:13am | 2 | 884k |
| 2nd Jun 2025 2025-06-02T09:13:11 | Final Director's Interest Notice Anshul Thakral | YesNo | 9:13am | 2 | 883k |
| 2nd Jun 2025 2025-06-02T08:44:26 | Opthea Provides Corporate Update | YesNo | 8:44am | 2 | 499k |
| 12th May 2025 2025-05-12T08:10:34 | Ceasing to be a substantial holder | YesNo | 8:10am | 17 | 1.3M |
| 30th Apr 2025 2025-04-30T08:53:33 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 8:53am | 8 | 1.6M |
| 10th Apr 2025 2025-04-10T09:21:24 | Opthea Provides Corporate Update | YesNo | 9:21am | 2 | 497k |
| 31st Mar 2025 2025-03-31T12:44:14 | Continuation of Suspension from Quotation | YesNo | 12:44pm | 1 | 112k |
| 31st Mar 2025 2025-03-31T12:41:44 | Opthea Announces Decision to Discontinue Wet AMD Trials | YesNo | 12:41pm | 3 | 503k |
About Opthea Ltd
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Dec 2024 | Lawrence Gozlan | Issued | 2,000,000 | $1,270,000 |
Issue of options.
|
| 17 Dec 2024 | Lawrence Gozlan | Expiry | 2,000,000 | $1,270,000 |
Options expired.
|
| 17 Dec 2024 | Jeremy Levin | Issued | 2,000,000 | $1,270,000 |
Issue of options.
|
| 17 Dec 2024 | Julia Haller | Issued | 1,000,000 | $635,000 |
Issue of options.
|
| 17 Dec 2024 | Susan Orr | Issued | 2,000,000 | $1,270,000 |
Issue of options. As per announcement on 17-12-2024
|
| 17 Dec 2024 | Quinton Oswald | Issued | 2,000,000 | $1,270,000 |
Issue of options. As per announcement on 17-12-2024
|
| 17 Dec 2024 | Anshul Thakral | Issued | 2,000,000 | $1,270,000 |
Issue of options.
|
| 17 Dec 2024 | Sujal Shah | Issued | 2,000,000 | $1,270,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Jul 2020 |
Mr. Gozlan, a biotechnology investor and advisor, is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr. Gozlan is also the Chief Investment Officer and Founder of Scientia Capital, a global investment fund focused exclusively on life sciences. Scientia was founded to provide expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. Prior to this, Mr. Gozlan was responsible for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte.
|
| Dr Jeremy Levin | Non-Executive ChairmanNon-Executive Director | Oct 2020 |
Dr. Levin has served as the Chief Executive Officer of Ovid Therapeutics Inc. since 2015, and since 2014, as Chairperson of the board of directors, of Ovid. From May 2012 to October 2013, Dr. Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to December 2012, Dr. Levin held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the executive committee at Bristol Myers Squibb Company.
|
| Mr Sujal Arun Shah | Non-Executive Director | Apr 2024 |
Mr. Shah is a biopharmaceutical executive with leadership and product development experience and a track record in capital formation that complements the expertise in retinal disease, especially wet AMD, of the Opthea Board. Most recently, Mr. Shah served as President and Chief Executive Officer of CymaBay Therapeutics which was acquired by Gilead Sciences for approximately $4.3 billion in total equity value in March 2024. Mr Sujal is chair of Risk Committee.
|
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | Nov 2024 |
Ms Connell is a commercial executive with business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Her track record of translating global commercial strategies into impactful business results and shareholder value will be instrumental as Opthea prepares for the topline data readout of its pivotal program of sozinibercept in wet AMD. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. She also serves as Non-Executive Director at Avecho Biotechnology Ltd (ASX: AVE), Proto Axiom (a biotech investment company with an incubation arm) and BioNSW (life sciences association for NSW, Australia).
|
| Mrs Karen Adams | Company SecretaryVice President of Finance | Jun 2021 |
-
|
| Dr Frederic Guerard | Chief Executive Officer | Oct 2023 |
-
|
| Judith Robertson | Chief Commercial Officer |
-
|
|
| Frederic Guerard | Chief Executive Officer |
-
|
|
| Peter Lang | Chief Financial Officer |
-
|
|
| Karen Adams | Company SecretaryVice President of Finance |
-
|
|
| Fang Li | Senior Vice President Regulatory Affairs |
-
|
|
| Julie Clark | Senior Vice President of Clinical Development |
-
|
|
| Bruno Gagnon | Senior Vice President Global Clinical Operations |
-
|
|
| Mark O'Neill | Vice President CMC |
-
|
|
| John Han | Vice President Medical Affairs |
-
|
|
| Kevin Bitter | Vice President Strategy & Corporate Development |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 180,041,041 | 14.62% |
| UBS Nominees Pty Ltd | 164,238,358 | 13.34% |
| HSBC Custody Nominees (Australia) Limited | 151,845,051 | 12.33% |
| JP Morgan Nominees Australia Pty Limited | 151,418,346 | 12.30% |
| BNP Paribas Noms Pty Ltd | 64,844,903 | 5.27% |
| HSBC Custody Nominees(Australia) Limited-Gsco Eda | 60,000,000 | 4.87% |
| National Nominees Limited | 52,933,500 | 4.30% |
| HSBC Custody Nominees (Australia) Limited-Gsi Eda | 43,877,058 | 3.56% |
| Merrill Lynch(Australia) Nominees Pty Limited | 42,764,892 | 3.47% |
| HSBC Custody Nominees (Australia) Limited A/C2 | 22,785,116 | 1.85% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 16,402,937 | 1.33% |
| Jagen Pty Ltd | 13,755,397 | 1.12% |
| Est Ms Margaret Lynette Harvey | 13,162,671 | 1.07% |
| HSBC Custody Nominees(Australia) Limited <Nt Comnwlth Super Corp A/C> | 12,420,253 | 1.01% |
| Buttonwood Nominees Pty Ltd | 11,311,250 | 0.92% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> i | 9,004,711 | 0.73% |
| Safo Investments Pty Ltd<Safo Investment A/C> | 8,134,875 | 0.66% |
| BNP Paribas Noms (Nz) Ltd | 6,840,745 | 0.56% |
| Armada Trading Pty Limited | 5,005,806 | 0.41% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> ii | 5,000,000 | 0.41% |